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Malnutrition is a major complication of peritoneal dialysis
(PD) and is associated with increased morbidity and
mortality. Daily losses of proteins and amino acids (AAs) into
dialysate contribute to this problem. Previous metabolic
balance study demonstrated that treatment with 1.1%
AA-based dialysis solution is safe and may improve protein
malnutrition in continuous ambulatory peritoneal dialysis
(CAPD) patients ingesting low protein intake. Other
prospective studies also showed that AA solution can provide
nutritional benefit for malnourished PD patients resulting
in a significant improvement in some biochemical and/or
anthropometric nutritional parameters. However, there
are other studies showing no particular improvement in
nutritional parameters after long-term use of AA solution.
This may be related to the differences in the study design,
sample size, methods used to assess nutritional status, and
other factors such as dietary intake and comorbidities of
study subjects. Published data will be reviewed to further
emphasize the nutritional benefit of long-term use of AA
solution in malnourished PD patients along with a brief
discussion on the various reasons that may partly explain
the different study results. We will also present the results
of a longitudinal observational study evaluating changes
in nutritional parameters following use of one exchange
of 1.1% AA solution in malnourished Korean PD patients.
A significant improvement of somatic protein status such as
lean body mass (LBM) and hand grip strength was observed.
No significant change in serum albumin level was noted.
Patients with a positive estimated coefficient for LBM in the
fitted regression model to the repeated observations over
1 year were classified as responders and patients with neutral
or negative coefficient were considered as non-responders.
Thirty-one out of 43 malnourished patients (72%) showed
nutritional benefit based on the change of LBM. Hand grip
strength and back lift strength were significantly higher in
responders at baseline. Other baseline parameters did not
differ between the two groups.
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Protein energy malnutrition is common in patients under-
going peritoneal dialysis and is associated with increased
morbidity and mortality.1–5 Poor dietary intake and loss of
nutrients into the dialysate are some of etiologic factors
known to contribute to malnutrition. Patients on PD are
reported to lose 3–4 g/day amino acids (AAs) and 4–15 g/day
of protein.6 One exchange with a 1.1% AA dialysis solution is
sufficient to compensate for these losses and to improve
nitrogen balance.7
Malnourished patients benefit from AA dialysis solu-
tions through peritoneal AA uptake7–13 and increased protein
anabolism associated with improvement in some biochemical
and/or anthropometric nutritional parameters.7,14 However,
this nutritional benefit from AA solutions was not uniformly
observed in long-term studies. This may be related to
study design, sample size, different methods used to assess
nutritional status, and other factors influencing nutritional
status such as adequacy of dialysis and inflammation.
In this paper, existing data will be reviewed to delineate
the current status of the potential nutritional benefits of AA
solutions. We will also present a preliminary study carried
out to ascertain potential factors influencing nutritional
status following AA use in malnourished PD patients.
CHARACTERISTICS OF AA SOLUTIONS AND PERITONEAL
TRANSPORT
PD patients are reported to lose 3–4 g/day of AAs and 4–15 g/
day of proteins.6 AAs were used to supplement theses
losses to maintain a positive nitrogen balance. The amount
of AA absorbed after 6 h of dwell time with a 1.1% AA
solution was 78.878% (approximately 16 g), which was
much greater than the peritoneal loss of AA after 6 h dwell
time with conventional glucose solutions (0.770.1 g of
total AA).15
Commercially available 1.1% AA solution (Nutrineal,
Baxter Healthcare Corporation) was designed to meet the
nutritional requirements of uremic patients.17 Peritoneal
ultrafiltration profile and transport characteristics of this
solution are similar to those of a 1.5% dextrose solution.15,16
NUTRITIONAL MARKERS INCLUDING BIOCHEMICAL
SURROGATE MARKERS
No single measure provides a comprehensive indication of
nutritional status. Measures of dietary intake, visceral and
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somatic protein stores, body composition, and functional
status identify different aspects of nutritional status. The
National Kidney Foundation-Kidney Disease Outcome
Quality Initiative (NKF-DOQI) Nutrition Practice Guide-
lines suggest that nutritional status in maintenance dialysis
patients be routinely assessed using serum albumin level,
percent usual body weight, percent standard body weight,
subjective global assessment (SGA), dietary interviews/
diaries, and normalized protein equivalent of total nitrogen
appearance.18 Serum levels of creatinine, cholesterol, total
protein, albumin, prealbumin, insulin-like growth factor-1,
and transferrin are commonly used biochemical surrogate
markers. Serum albumin level is a valid and clinically
useful measure of protein-energy nutritional status in
maintenance dialysis patients and stabilized serum albumin
is a measure of visceral protein pool size. However, serum
albumin is also influenced by liver function, peritoneal
loss, and/or, inflammatory status.19 Acute or chronic
inflammation limits the specificity of serum albumin as a
nutritional marker.
Anthropometric measurements such as percent usual
body weight, percent standard body weight, body mass
index, skin fold thickness, and mid-arm circumference
are valid and clinically useful indicators of protein energy
nutritional status in maintenance dialysis patients. Normal-
ized protein equivalent of total nitrogen appearance is
used as an indicator of net protein degradation and
protein intake. SGA is a simple, valid, and clinically useful
tool to measure the global nutrition status of main-
tenance dialysis patients. A higher SGA score has been
associated with a lower relative risk of death and fewer
hospitalized days per year.20 Table 1 shows recommended
measures for monitoring nutritional status of maintenance
dialysis patients.18
NUTRITIONAL EFFECTS OF AA SOLUTION
Several studies have shown that AA solutions provide a
nutritional benefit at least in the short term.7,12,21,22
Improvement in protein nutrition with AA-based dialysate
was clearly demonstrated in a metabolic balance study of
malnourished patients on continuous ambulatory peri-
toneal dialysis (CAPD) with low protein intake.7 At baseline,
patients were in neutral nitrogen balance and net protein
anabolism was positive as determined from 15N-glycine
studies. After commencing intraperitoneal AA therapy,
nitrogen balance became significantly positive, net protein
anabolism increased significantly, fasting morning plasma AA
pattern became more normal, and serum total protein and
transferrin concentrations rose. Patients generally tolerated
the treatment well, although some patients developed mild
metabolic acidemia. Skeletal muscle AA uptake was increased
after 6 weeks use of a 1.1% AA solution both in the fasting
state and during insulin stimulation in 10 stable non-diabetic
CAPD patients.21
A prospective randomized study of a 1.1% AA solution for
3 months in malnourished CAPD patients showed an
increase in serum insulin-like growth factor-1 level and
significant decreases in serum potassium and inorganic
phosphorus levels, indicating a general anabolic response.12
In patients with baseline albumin levels less than 3.5 g/dl,
patients using the AA solution showed increases in albumin,
transferrin, and prealbumin levels relative to baseline values,
whereas these serum protein levels were unchanged with
glucose solutions.
In an acute 3H-phenylalanine kinetic study,23 it was
reported that muscle protein synthesis increased by 20%
during the use of AA solution. This increase was related
to a significant increase in total arterial AA level and a
reduced AA release from muscle. In the same study, a 20%




Measurements that should be performed routinely Predialysis or stabilized serum albumin Monthly
in all patients Percent of usual post-dialysis (MHD) or post-drain (CPD) body weight Monthly
Percent of standard (NHANES II) body weight Every 4 months
SGA Every 6 months
Dietary interview and/or diary Every 6 months
nPNA Monthly MHD; every
3–4 months CPD
Measures that can be useful to confirm or extend Predialysis or stabilized serum pre-albumin As needed
the data obtained from the measures Skin fold thickness As needed
in Category I Midarm muscle area, circumference or diameter As needed
SGA As needed
Dual energy X-ray absorptiometry As needed
Clinically useful measures, which, if low, might Predialysis or stabilized serum
suggest the need for a more rigorous Creatinine As needed
examination of protein-energy nutrition status Urea nitrogen As needed
Cholesterol As needed
Creatinine index As needed
CPD, continuous peritoneal dialysis; nPNA, normalized protein nitrogen appearance; NHANES, National Health and Nutrition Examination Survey; SGA, subjective global
assessment.
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decrease in muscle protein synthesis, a 20–25% decrease in
arterial AA level, a persistent negative net protein balance,
and a decrease in the efficiency of muscle protein turnover
were found during PD with glucose solutions alone. A short-
term use of AA solution was also effective in improving net
protein balance and converting nitrogen balance from
negative to positive in patients on automated peritoneal
dialysis.14
Six-month use of AA solution showed a trend towards
improvement in mid-arm muscle circumference and a
significant increase in serum albumin level in patients with
serum albumin less than 30 g/l.24 AA solution improved
oxidative phosphorylation of muscle during exercise and
recovery in nutritionally unselected stable PD patients.25
However, there are other studies showing no improvement in
nutritional parameters after 6 months use of AA solution in
well-nourished CAPD patients despite increased serum
concentration of AA26 or no change in serum albumin level
in stable CAPD patients.27
A 3-year prospective randomized study in malnourished
CAPD patients showed that biochemical nutritional para-
meters including albumin and cholesterol level remained
stable or increased in patients using an AA solution once
daily, but decreased in patients with conventional dextrose
solutions.28
POTENTIAL FACTORS AFFECTING NUTRITIONAL BENEFIT
OF AA SOLUTION
Firstly, as there is no single parameter to measure
comprehensive nutritional status, parameters used in clinical
studies vary widely, and single or a few of those parameters
may reflect limited aspects of complex nutritional status.
Secondly, the relatively small sample size in most clinical
studies may provide poor statistical power. Thirdly, study
design may affect the study outcome. Most clinical studies
have been observational nature. Some studies were carried
out in malnourished patients and the other studies carried
out in either stable or nutritionally unselected patients.
Fourthly, although dietary intake is the most important
factor in determining nutritional status, consistent dietary
control and monitoring are difficult especially in long-term
studies. In addition, comorbid conditions such as peritonitis,
heart failure, and infectious illness during the study period
are also hindrances of nutritional studies.
Recently, two different categories of malnutrition were
suggested: malnutrition related to inflammation (type II) and
malnutrition not related to inflammation (type I).29 A
nutrient supplement, either dietary or peritoneal, is helpful in
reverting nutritional status in type I malnutrition whereas it
is not sufficient in type II malnutrition patients without
correction of the causes of inflammation. The inflammatory
status of patients has not been well studied.
Furthermore, protein anabolism after AA supplementa-
tion is improved with a sufficient calorie intake. Therefore, to
maximize AA utilization for protein anabolism, it is
recommended that an AA solution be used during the day
with sufficient dietary energy intake. A recent study using AA
plus glucose dialysis solution obtained by cycler-assisted
mixing of one bag of 2.5 l of AA and four bags of 2.5 l glucose
showed improved net protein balance and a positive
conversion of nitrogen balance.14
All of the above-mentioned factors and conditions
can potentially influence the nutritional benefit of an AA
solution and may partly explain the differences observed in
clinical studies.
OTHER BENEFITS OF AA SOLUTIONS
A non-glucose AA solution has positive effects on fat
metabolism. Plasma cholesterol level and triglyceride level
decreased during the use of AA solution for 3 months,30
6 months,27 or 3 years.28 Another 6-month study showed
a significant decrease in total body fat mass during the use
of an AA solution, whereas it increased during the use of
glucose solutions.31
A LONG-TERM CLINICAL STUDY INVESTIGATING FACTORS
AFFECTING NUTRITIONAL EFFECTS OF AA SOLUTION
As there is no single parameter that can measure compre-
hensive nutrition status, parameters used in clinical studies
vary widely, and single or a few of those parameters may
reflect limited aspects of complex nutritional status.
Although there are several studies showing some nutritional
benefit of AA solutions in PD patients, the long-term efficacy
of AA solutions is not yet clear. Moreover, there may be a
group of patients who gain more nutritional benefits with AA
solutions than others. It would be useful clinically to identify
factors that play a critical role in determining the effect of
AA solutions on nutritional status. To gain further insight
on these factors, we carried out a long-term observational
study in 46 malnourished CAPD patients (mean age,
53.278.6 years and mean PD duration, 75.1734.6 months).
Malnourished patients were identified as patients meeting
two or more of the following: (1) serum albumin concentra-
tion o3.5 g/dl; (2) normalized protein equivalent of total
nitrogen appearance o1.0 g/kg/day; (3) SGA score o5. A
1.1% AA solution was used once daily for 1 year. To evaluate
general nutritional status during the study, biochemical,
dialysis, anthropometric, and nutritional parameters includ-
ing dietary calorie/protein intake were assessed at baseline
and every 3 months. Parameters at baseline and at the end of
the study were compared. In order to ascertain factors
determining the efficacy of the AA solution, patients were
classified as either responders or non-responders. Change in
lean body mass (LBM) estimated by creatinine kinetics was
used as an ultimate nutritional parameter in this study.
Depending on the direction of changes in LBM, patients were
divided into two groups by applying the regression model to
the repeated observations for each patient over a year.
Patients with a positive estimated coefficient for LBM in the
fitted regression model was classified as responders and
patients having neutral or negative estimated coefficient were
classified as non-responders.
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RESULTS
Mean values of blood urea nitrogen, creatinine, LBM, % LBM,
normalized protein equivalent of total nitrogen appearance,
serum IGF-1 level, back lift strength, and SGA score increased
significantly over 12 months (Table 2). Thirty-one patients
were identified as responders and 12 as non-responders.
Hand grip strength and back lift strength were significantly
higher in responders at baseline. Residual renal function was
Table 2 | Changes of biochemical, nutritional and adequacy parameters in 46 malnourished CAPD patients using AA solutions
for 1 year
Parameters Baseline 3 months 6 months 9 months 12 months
BUN (mg/dl) 49.6714.1 70.2711.9w 70.1715.0w 69.8715.7w 72.1714.6w
Cr (mg/dl) 10.272.1 10.472.6 10.872.7w 11.372.8w 11.772.8w
Protein (g/dl) 6.470.6 6.370.5 6.270.5 6.370.6 6.270.6
Albumin (g/dl) 3.370.3 3.370.2 3.270.3 3.270.3 3.270.3
Prealbumin (mg/dl) 50.6715.6 50.6715.6 49.6717.9 47.9717.3 47.3714.2
Hemoglobin (g/dl) 8.971.4 8.972.0 9.371.9 9.571.2 9.571.5
Potassium (meq/l) 4.170.5 3.970.5 4.070.7 4.070.6 4.070.6
Phosphorus (mg/dl) 4.571.1 4.371.1 4.371.2 4.371.1 4.471.1
IGF-1 (ng/ml) 191798 207793w 2007103 2787120w 286794w
Total CO2 (meq/l) 26.473.2 24.672.3
w 25.772.5 25.273.1 23.872.3w
C-reactive protein (mg/dl) 0.4970.32 0.4170.41 0.6871.24 0.3270.29 0.3570.38
LBMCr (kg) 40.576.9 42.178.8w 41.878.0w 43.478.7w 43.978.5w
LBMCr (% BW) 69.678.3 71.8710.3w 72.379.3w 73.979.8w 74.079.7w
nPNA (g/kg/day) 0.970.1 1.270.1w 1.270.1w 1.270.1w 1.270.1w
SGA 5.170.9 5.4 70.7w 5.670.8w 5.770.6w 5.970.6w
Hand grip strength (kg) 21.676.6 23.477.6w 23.477.5w 21.677.8 21.177.2
Back lift strength (kg) 57.6724.4 64.4728.0w 67.7726.1w 63.7726.7w 63.0727.1w
Dialysis parameters
Weekly Kt/V 2.170.36 2.170.37 2.170.26 2.170.26 2.070.36
SCCr (l/wk/1.73m2) 69.4711.4 70.5714.5 68.0713.0 66.9712.7 64.5712.2w
Anthropometry
LBM-anthro (kg) 44.176.8 43.876.4 43.775.8 44.576.4 46.176.5
Mid-arm Cx (cm) 25.673.4 26.073.4 26.173.6 26.173.7 27.373.3
Dietary intake
Calorie (kcal/kg/day) 28.473.1 23.673.3 23.474.6 24.273.7 24.674.8
Protein (g/kg/day) 0.870.1 0.870.1 0.870.1 0.870.1 0.970.2
AA, amino acid; BUN, blood urea nitrogen; CAPD, continuous ambulatory peritoneal dialysis; IGF-1, insulin-like growth factor-1; LBM-anthro, lean body mass calculated by
anthropometric measurements; Mid-arm Cx, mid-arm circumference; nPNA, normalized protein nitrogen appearance; SCCr, standardized creatinine clearance; SGA, subjective
global assessment; wk, week.
wPo0.05 compared with baseline.
Table 3 | Comparison of parameters between responders and non-responders
Responders (n=31) Non-responders (n=12)
At baseline During AA At baseline During AA
BUN (mg/dl) 49.2714.2 72.3712.6w 50.0714.3 67.1712.0w
Cr (mg/dl) 10.672.0 11.872.6w 9.772.1 9.772.3
Protein (g/dl) 6.670.7 6.370.5 6.270.5 6.270.4
Albumin (g/dl) 3.470.2 3.370.2 3.270.3 3.270.2
LBMCr (kg) 41.677.7 44.978.9w 39.275.9 39.176.2
% LBMCr 70.878.9 76.479.1w 68.177.6 68.477.5
nPNA (g/kg/day) 0.970.1 1.270.1w 0.970.1 1.170.1w
TCO2 (mmol/l) 26.873.3 25.071.5 25.873.0 24.871.6
SGA 5.270.7 5.870.6w 5.071.1 5.470.7w
Hand grip strength (kg) 23.277.3z 24.377.7w 19.775.3z 19.376.1
Back lift strength (kg) 67.0727.4z 75.3726.6w 46.4713.9z 49.1712.9
Weekly Kt/V 2.070.2 2.170.2 2.170.3 2.170.3
SCCr (l/wk/1.73m2) 66.977.4 65.979.0 72.3715.1 70.8714.3
Dietary calorie intake (kcal/kg/day) 23.872.7 23.973.0 23.173.1 24.673.8
Dietary protein intake (g/kg/day) 0.870.1 0.870.1 0.870.1 0.870.2
RRF (ml/min) 0.3070.80 NA 0.0370.20 NA
AA, amino acid; BUN, blood urea nitrogen; LBM-anthro, lean body mass calculated by anthropometric measurements; NA, not available; nPNA, normalized protein nitrogen
appearance;RRF, residual renal function; SCCr, standardized creatinine clearance; SGA, subjective global assessment; wk, week.
RRF calculated as 1/2(creatinine+urea clearances).
wPo0.05 for comparison of baseline and after AA; zPo0.05 for comparison between responders and non-responders at baseline.
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negligible in both groups, but more patients had some
residual renal function in responders. Other parameters did
not differ between the two groups (Table 3). In summary,
several nutritional parameters including LBM, back lift
strength, and SGA improved following use of the AA
solution. Thirty-one of 43 patients (72%) showed nutritional
benefit based on the changes of LBM, especially in those with
better muscle strength and higher residual renal function at
baseline.
CONCLUSION
It can be concluded that long-term use of an AA dialysis
solution can induce improvement of nutritional status in a
substantial number of PD patients. Use of AA dialysis
solution is associated with an increase in serum AA level,
improved nitrogen balance, maintenance of serum albumin
level, and maintenance, or improvement of LBM. Improve-
ment in nutritional status with AA solution can be expected
in mild to moderately malnourished patients who maintain
relatively good muscle strength with some residual renal
function. In our study, a declining trend in serum albumin
level and LBM observed during the pre-AA solution period
was stabilized or improved in the responders (data not
shown).
Conflicting results of various clinical studies may reflect
the complexity of nutritional status that cannot be measured
by one or only a few of the known parameters.
There are other benefits of using AA solutions such as
improved fat metabolism inducing lesser atherosclerotic
burden. The potential benefit of an AA solution as a non-
glucose osmotic agent to preserve membrane function and to
reduce glucose load in long-term PD patients deserves
further evaluation.
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